Well Researched

CJC-1295 (without DAC)

Short-Acting Growth Hormone Releasing Hormone Analog | Modified GRF 1-29

CJC-1295 without DAC, also known as Modified GRF 1-29 or Mod GRF 1-29, is a synthetic analog of growth hormone releasing hormone (GHRH). This short-acting variant stimulates pulsatile growth hormone release, mimicking the body's natural GH secretion patterns. Unlike its DAC-modified counterpart, this version has a brief half-life of approximately 30 minutes, allowing for more precise control over growth hormone pulses and reduced risk of receptor desensitization.

Daily dose

100-300mcg per injection

Frequency

2-3 times daily

Cycle length

12-16 weeks

Storage

2-8°C (refrigerated)

Key benefits

Preserves natural GH pulsatility, minimal side effects, no receptor desensitization, precise control over GH release

How it works

Binds to GHRH receptors on somatotroph cells, stimulating cAMP production and triggering growth hormone release in physiological pulses

Dosage protocols

Goal

Anti-Aging/Wellness

Dose

100mcg · 2x daily (morning and bedtime)

Route

Subcutaneous

Goal

Body Composition

Dose

100-150mcg · 3x daily (morning, post-workout, bedtime)

Route

Subcutaneous

Goal

Maximum GH Release

Dose

200mcg · 2-3x daily with GHRP

Route

Subcutaneous

Goal

Sleep Enhancement

Dose

100-200mcg · Once at bedtime

Route

Subcutaneous

Research indications

growth Hormone

Natural GH Pulse Restoration — Stimulates physiological growth hormone pulses that decline with age

IGF-1 Elevation — Increases insulin-like growth factor 1 levels through enhanced GH secretion

Pituitary Function Support — Maintains healthy pituitary-somatotroph axis without suppression

anti Aging

Muscle Mass Preservation — Supports lean muscle maintenance through enhanced protein synthesis

Bone Density Support — May help maintain bone mineral density through GH/IGF-1 pathway

Skin Elasticity — Potential improvements in skin thickness and collagen production

recovery

Exercise Recovery — Enhances post-workout recovery through improved protein synthesis

Sleep Quality — May improve deep sleep stages when administered before bed

Injury Healing — Supports tissue repair through growth factor cascade activation

Administration

injectable

Interactions

Synergistic

Ipamorelin — Excellent combination - Ipamorelin (GHRP) + CJC-1295 (GHRH) provides complementary GH release through different receptor pathways

Synergistic

GHRP-6 — Strong synergy when combined - GHRP-6 amplifies the GH pulse initiated by CJC-1295

Synergistic

GHRP-2 — Potent combination for maximizing growth hormone release through dual pathway activation

Monitor Combination

Hexarelin — Can be combined but monitor for excessive GH elevation due to Hexarelin's potency

Avoid Combination

CJC-1295 with DAC — Never combine different CJC-1295 variants - choose based on desired release pattern

Use Caution

Tesamorelin — Both bind to pituitary GHRH receptors. Combining saturates receptors without amplifying GH release, risking receptor desensitization and blunted pulsatility. Choose one based on your protocol goals.

Compatible

MK-677 — Different mechanisms - MK-677 provides continuous ghrelin stimulation while CJC-1295 offers pulsatile GHRH

Safety notes

Generally well-tolerated with minimal side effects at recommended doses

May cause temporary facial flushing or warmth for 5-10 minutes post-injection

Monitor blood glucose if diabetic - GH can affect insulin sensitivity

Not recommended for those with active cancer due to growth-promoting effects

Avoid if you have diabetic retinopathy or severe kidney disease

Research studies

Long-term Safety Profile of Modified GRF Analogs (2015)

Animal model | 6 months | Daily administration

No significant adverse effects on pituitary morphology or function with chronic use, supporting the safety of long-term pulsatile GHRH analog administration.

Comparative Analysis: CJC-1295 vs Native GHRH (2010)

In vitro + Human | Various doses | Receptor binding assays

Found CJC-1295 without DAC had 4x greater receptor affinity than native GHRH and enhanced resistance to enzymatic degradation, explaining its superior efficacy.

Growth Hormone Pulsatility with Mod GRF 1-29 (2008)

Human | 100mcg 3x daily | 30 days | 24 subjects

Showed preservation of natural GH pulsatility patterns when administered 3 times daily, with no evidence of pituitary desensitization over the study period.

Pharmacokinetics of Modified GRF(1-29) in Healthy Adults (2006)

Human | 100-200mcg | Single dose | 12 subjects

Demonstrated rapid absorption with peak GH levels at 15-30 minutes post-injection, establishing the short half-life profile and optimal dosing frequency for pulsatile GH release.

Related compounds

CJC-1295 with DAC Ipamorelin CJC-1295 (no DAC) / Ipamorelin Protocol Sermorelin